company background image
UR8 logo

UroGen Pharma DB:UR8 Stock Report

Last Price

€13.50

Market Cap

€497.6m

7D

4.7%

1Y

81.2%

Updated

23 Mar, 2024

Data

Company Financials +

UR8 Stock Overview

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers.

UR8 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health2/6
Dividends0/6

UroGen Pharma Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for UroGen Pharma
Historical stock prices
Current Share PriceUS$13.50
52 Week HighUS$21.20
52 Week LowUS$7.10
Beta1.1
1 Month Change-15.63%
3 Month Change0.75%
1 Year Change81.21%
3 Year Change-16.15%
5 Year Change-58.84%
Change since IPO-71.15%

Recent News & Updates

Recent updates

Shareholder Returns

UR8DE BiotechsDE Market
7D4.7%4.5%1.4%
1Y81.2%34.0%7.5%

Return vs Industry: UR8 exceeded the German Biotechs industry which returned 31.8% over the past year.

Return vs Market: UR8 exceeded the German Market which returned 5.5% over the past year.

Price Volatility

Is UR8's price volatile compared to industry and market?
UR8 volatility
UR8 Average Weekly Movement10.6%
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.2%
10% least volatile stocks in DE Market2.4%

Stable Share Price: UR8's share price has been volatile over the past 3 months.

Volatility Over Time: UR8's weekly volatility has decreased from 24% to 11% over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2004200Liz Barretthttps://www.urogen.com

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company’s lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC).

UroGen Pharma Ltd. Fundamentals Summary

How do UroGen Pharma's earnings and revenue compare to its market cap?
UR8 fundamental statistics
Market cap€497.65m
Earnings (TTM)-€94.62m
Revenue (TTM)€76.54m

6.5x

P/S Ratio

-5.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
UR8 income statement (TTM)
RevenueUS$82.71m
Cost of RevenueUS$9.36m
Gross ProfitUS$73.35m
Other ExpensesUS$175.60m
Earnings-US$102.24m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-3.00
Gross Margin88.68%
Net Profit Margin-123.61%
Debt/Equity Ratio-151.1%

How did UR8 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.